Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.36 - $0.65 $29,016 - $52,390
80,600 Added 144.96%
136,200 $49,000
Q1 2024

May 15, 2024

BUY
$0.42 - $1.38 $1,680 - $5,520
4,000 Added 7.75%
55,600 $37,000
Q4 2023

Feb 14, 2024

SELL
$0.3 - $0.63 $14,220 - $29,862
-47,400 Reduced 47.88%
51,600 $27,000
Q3 2023

Nov 14, 2023

BUY
$0.58 - $1.47 $32,073 - $81,291
55,300 Added 126.54%
99,000 $59,000
Q2 2023

Aug 14, 2023

BUY
$1.11 - $1.74 $12,321 - $19,314
11,100 Added 34.05%
43,700 $56,000
Q1 2023

May 15, 2023

SELL
$1.66 - $3.67 $43,658 - $96,521
-26,300 Reduced 44.65%
32,600 $57,000
Q4 2022

Feb 14, 2023

BUY
$2.77 - $5.07 $31,855 - $58,305
11,500 Added 24.26%
58,900 $184,000
Q3 2022

Nov 14, 2022

SELL
$4.27 - $6.39 $57,644 - $86,265
-13,500 Reduced 22.17%
47,400 $232,000

Others Institutions Holding SGMO

About SANGAMO THERAPEUTICS, INC


  • Ticker SGMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 156,552,992
  • Market Cap $313M
  • Description
  • Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...
More about SGMO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.